Life Sciences Archive » November, 2010

Life Sciences - November, 2010

155 articles

• Doctor Indicted Over False Fen-Phen Injury Claims
• Novartis Wins OK On $175M Deal To End Bias Action
• AIDS Nonprofit Says BMS Overcharged For Drugs
• J&J Units Target Impax Over Generic Concerta
• AMAG Updates Feraheme Label To Include Safety Risks
• Insurer's Bid To Recoup $15M Sprint D&O Payout Nixed
• Allergan, AMD, Bosch Face False Marking Suits
• Alzheimer's Group Hits UPenn, Avid With Patent Suit
• J&J Must Pay Basilea $130M Over License: Dutch Court
• Cardinal Health Buys Chinese Drug Importer For $470M
• New EU Rule Eases Biosimilar Development
• The Continuing Struggle For D&O Coverage
• Syntrix Slaps Illumina With Biotech Patent Suit
• Coventry Wins Partial Toss Of Copay Class Action
• Federal Circ. Fleshes Out Prosecution Laches
• Nev. High Court Affirms $58M Award Against Wyeth
• Novartis Hit With $1M Ruling In Aredia, Zometa Suit
• J&J Recalls 9M Tylenol Meds Over Missing Alcohol Label
• FDA Crime Head To Depart Amid Misconduct Claims
• Sonova Recalls Cochlear Implants Made By US Unit
• Genzyme, Daiichi Sankyo Fight More Welchol ANDAs
• Judge Won't Rehear Dismissal Bid In Wyeth Pristiq Suit
• 7th Circ. Pins Down Atty Fee Awards In Lanham Case
• J&J Pulls Children's Benadryl, Motrin Off Shelves
• Philly Judge Nixes GSK Paxil Birth Defect Suit
• Pharma Struggles To Escape FCPA Net
• Implant Maker Seeks To Subpoena Dickstein In IP Spat
• Attorneys Brace For Surge In Sex Bias Class Actions
• Wyeth Appeals Retaliation Trial Order To High Court
• Amgen Loses Bid To Wrap Up Teva Patent Fight
• FCA Settlements Top $3B In FY2010
• Life Tech Sues GenMark Over DNA Test Patent
• Avandia Plaintiffs Must Comply With Lone Pine Order: Judge
• Merck Picks Up Another Win In Fosamax Bellwether
• Darvon Maker Pulls Painkiller From US Market
• W.Va. High Court Nixes $4.5M Verdict Against J&J Unit
• Bristol-Myers Hit With False Marking Suit Over 3 Drugs
• CIBC Continues To Dog Attys In Chem Rx Ch. 11
• Merck Unit Sues TriGen Over Folic Acid Patents
• Class Attys Score $38M Fee In Novartis Sex Bias Suit
• EU Drug Agency OKs Rule On Biosimilar Antibodies
• Vioxx Plaintiffs Take $5B Deal Woes To High Court
• King Investors Fail To Speed Suit Over $3.6B Pfizer Sale
• Jones Day Lures Biotech IP Partners From McDermott
• Bristol-Myers Sales Rep Sues For Overtime Pay
• Ropes Gray Reps Genzyme In $265M Diagnostics Sale
• France Says Diabetes Drug May Have Led To 500 Deaths
• Smith & Nephew Loses 2nd Bid To Kill FCA Dispute
• Siga Says Survey Will Bolster Bid For $2.8B Contract
• Wachtell Reps Cardinal Health In $1.3B Kinray Buy
• Upsher-Smith Faces False Marking Suit Over Diet Drug
• 2nd Circ. Remands State Claims In Pfizer Firing Suit
• The Challenges Of FDA's Nascent Biosimilars Regime
• Ameritox To Pay $16M To Resolve Medicaid FCA Suit
• Rituxan Wrongful Death Suit Stays In Federal Court
• Greenberg Adds Veteran Senate Atty To Health Group
• $3M Bail Set For Doctor Accused Of Tipping Off Fund
• Stanford Appeal Reignites IP Custody Battle
• Ex-Baseball Player Gets 9 Years For Medicare Fraud
• FDA Accused Of Contempt In Plan B Availability Case
• Settlement Funds Established In Avandia MDL
• Stryker Can't Nix USPTO Ruling In Bone Screw IP Row
• Lilly Chemotherapy Drug Patent Valid, Judge Rules
• Merck, Schering-Plough Hit With False Marking Suit
• Judge Clears Path For Generic Dr. Reddy's Asthma Drug
• CIBC Fights Fox Rothschild Fees In Chem Rx Ch. 11
• Healthfirst Hands Over $7.7M In Marketing Rep OT Suit
• FDA Seeks To Improve Safety Of Heart Defibrillators
• Otsuka Triumphs In Abilify Patent Litigation
• Pay-For-Delay Is Smart And Legal, Drugmakers Argue
• Hospira Sues Caraco To Block Generic Precedex
• Flonase Purchasers Win Class Cert. In Suit Against GSK
• Medicare Fraud Units Will Scrutinize Health Care Cos.
• Doctor Preps Bail Package In Hedge Fund Tip-Off Case
• Utah Slaps GSK With Medicaid Fraud Suit Over Avandia
• BASF Dodges Claims From Vitamin Cartel Victims
• Smith & Nephew Asks Court To Rethink FCA Ruling
• US Reversal Frames Issues In Myriad's Appeal
• GSK Atty Indictment May Paralyze Lawyers
• FDA Releases Raw Heparin Shipments To Amphastar
• Convicted Pharma Fraudster Seeks Post-Trial Acquittal
• Teva, Others Settle With Counties In Medicaid MDL
• Hawaii Sues McKesson For Allegedly Inflating AWPs
• AstraZeneca Hits Watson With Crestor Patent Suit
• Pfizer Fights Whistleblower Retaliation Suit In 2nd Circ.
• Fed. Circ. Revives Merck Suit Over Temodar Patent
• Cobalt's Generic Boniva Barred In Roche IP Spat
• Mylan Reaches $2.6M Deal In Mass. Medicaid Case
• Stanley Black & Decker Hit With False Marking Suit
• Fed. Circ. Nixes Abraxis Win In Naropin Patent Row
• Feds Hit Back At Stryker Biotech's Dismissal Bids
• DC Circ. Upholds Exclusivity For ADHD Drug Vyvanse
• Abbott, Others Argue For New Inequitable Conduct Rule
• Omnicare Investors Drop High Court Appeal
• Ex-GSK Atty Indicted For Obstructing Federal Probe
• Class Action Alleges Dexatrim Contains Carcinogen
• FDA Warns Claris Over Contaminated Drugs
• FDA Got Too Close To Drug Firms: GAO
• House Leaders To Probe FDA's Puerto Rico Office
• Navy Defends Decision To Nix $15M Drug Test Deal
• Q&A With Dechert's Sean Wajert
• FDA Blames GE, Toshiba Radiation Problems On Misuse
• Wyeth Effexor Patent Valid, Infringed: Australian Judge
• Novo Nordisk, Actavis End PrandiMet Patent Spat
• DOJ Ends Reagents Antitrust Probe Into Immucor
• The Trend Toward Using The Risk-Utility Test
• AAI Urges FTC To Reconsider CVS Caremark Merger
• Edwards Lifesciences Subpoenaed Over Heart Monitor
• Centocor Loses Bid To Dismiss Remicade Suit
• Inequitable Conduct Doctrine Takes Stage In Fed. Circ.
• Siga Appeals $2.8B Drug-Contract Disqualification
• Whistleblowers Seek To Revive Suit Against Medco
• Q&A With Dinsmore & Shohl's James Zeszutek
• Weil Gotshal Advises Lilly In $800M Avid Deal
• Ex-Bristol Myers Worker Pleads Guilty To IP Theft
• Dendreon Inks $17M Deal In Shareholder Action
• FDA Falls Short On Medical Device Monitoring: Report
• Q&A With Cahill's Bart Friedman
• Akzo, AstraZeneca Face 'Dead Peasant' Policy Suit
• Pharmacy's Provigil Action To Remain In Federal Court
• Astellas Targets Glenmark Over Eczema Drug
• Smith & Nephew Fails To Shake Whistleblower Suit
• Class Can't Kill Plaintiffs Atty's AWP Ban Appeal
• Oracle Ex-Pres. Says Bilked Software Worth Billions
• KV Securities Plaintiffs Fight Denial Of Bid To Amend
• Ex-Biggest Loser Ends Spat With Another Diet Co.
• The Government Stance On Generic Preemption
• Valeant Settles Biovail Frivolous Suit Claims For $10M
• Judge Squashes Hostess Trans Fat Labeling Suit
• Allergan's Bid For New Trial Rejected In Zymar Case
• MDL Judge Wants More Info On Zicam Settlement
• Q&A With Kelley Drye's Julian Solotorovsky
• Genzyme Sues Lupin Over Generic Welchol
• Watson Reaches Deal With J&J For Concerta Generic
• 5th Circ. Revives Cardinal Health Qui Tam Suit
• Fosamax Judge Restricts Bellwether Trial Evidence
• Thermo Fisher Hit With Patent Suit Over Lab Device
• DOJ's Policy Shift Could Change Future Of DNA IP
• Chem Rx's $70M Sale To PharMerica Gets Green Light
• FDA Starts On Path To Approving Biosimilars
• French Doctor Busted For Allegedly Selling Inside Tips
• Mylan Drops Appeal In Generic Paxil Contract Fight
• CareFusion Antitrust Claims Nixed In Medtronic Suit
• Oracle, SAP Face Off Over Infringement Damages
• Fed. Circ. Denies Lilly En Banc Review In Gemzar Feud
• FDA Issues Class I Recall Of Medtronic's Octopus Nuvo
• Fed. Circ. Upholds Injunction On Generic Pulmicort
• Skadden Reps McKesson In $2B US Oncology Deal
• Supreme Court Disbars Former Fen-Phen Torts Atty
• Pfizer Recalls 38,000 More Bottles Of Lipitor
• Fresenius Goes After Lupin Over PhosLo ANDA
• DOJ Urges Compromise In Gene Patent Appeal Brief
• High Court To Weigh Rights In Gov't-Funded Inventions
• Thoughts On Say-On-Pay Frequency
• Increasing Scrutiny Of Gov't Contingent Fee Deals